Sun Pharmaceutical Industries Limited has released its investor presentation, dated December 26, 2025. The presentation offers insights into the company’s operations, financial performance, and strategic focus areas. Key highlights include the company’s global presence, diversified business segments, and commitment to research and development. The presentation is available on the company’s website.
Company Overview
Sun Pharma is positioned as a leading global specialty generic company with operations spanning over 100 countries. The company’s business is diversified, encompassing innovative medicines, branded generics, generics, and APIs. Sun Pharma emphasizes a focused therapy approach with a fast-growing portfolio of innovative medicines.
Financial Performance
Sun Pharma’s revenue base is well-diversified across various geographies, with India contributing 33%, the US 31%, Emerging Markets 18% and Rest of World 14% of the total revenue for FY25. The company’s sales for FY25 stood at Rs 520 Bn.
Key Financial Highlights
The company has demonstrated a strong track record of growth. Here’s a snapshot of key financial metrics:
- Sales: CAGR of 19% from FY10 to FY25
- EBITDA: CAGR of 18% from FY10 to FY25
- Adjusted Net Profit: CAGR of 16% from FY10 to FY25
Sun Pharma also maintains strong profitability and return ratios. The adjusted net profit margin for FY25 was 22.8%, with a market cap of USD 49.2 Bn as of March 31st.
Business Segments
Sun Pharma operates across several key geographies:
- US Formulations: FY25 sales of Rs 162,403 mn
- India Formulations: FY25 sales of Rs 169,230 mn and largest pharma company
- Emerging Markets: FY25 sales of Rs 94,160 mn, operating at scale in over 80 countries.
- Rest of World: FY25 sales of Rs 71,626 mn.
Innovative Medicines
Innovative Medicines contribute significantly to Sun Pharma’s portfolio, with 27 products marketed globally. The company continues to invest in R&D to develop new and innovative therapies.
R&D and Manufacturing
Sun Pharma is committed to R&D, with a cumulative spend of approximately Rs 320 Bn to date. The company has 40 manufacturing facilities and has a strong focus on quality compliance.
Strategic Focus Areas
Sun Pharma is focused on key strategic objectives, including:
- Enhancing the share of innovative/branded business.
- Focusing on productivity enhancement in the Indian market.
- Gaining critical mass in key emerging markets.
Source: BSE
